Most Recent
Former executives of wealth manager IOOF facing disqualification proceedings by the Australian Prudential Regulation Authority have criticised the prudential regulator for a late and extensive discovery request, saying it could "imperil" the July trial date.
Former IOOF chairman George Venardos will be allowed to object to incriminating evidence and discovery in proceedings brought by APRA, after a court found there was a real and appreciable risk that ASIC could also bring a civil case against him.
Engineering firm Jacobs E&C, which was acquired by WorleyParsons last year, has said it will resist an arbitration judgment of around $132 million handed down against it in March to the operator of a Vietnamese mine.
APRA has been ordered to hand over all of its correspondence with fellow regulator ASIC relating to former IOOF chairman George Venardos, as he prepares to argue privilege over discovery that might incriminate him in any possible ASIC proceedings.
The Bank of Queensland has criticised a judgment which found the bank's insurance policy left it on the hook for a $6 million settlement of a class action brought by investors in a multi-million dollar Ponzi scheme by jailed fraudster Bradley Sherwin.
The former chairman of troubled IOOF told APRA during a review meeting that he "struggled" to think the wealth manager had any conflicts of interest and that the issue was getting too much "airplay", according to court documents filed recently by the prudential regulator.
After losing its fight for a temporary injunction, Sanofi-Aventis has dropped its patent lawsuit against Alphapharm over the generic drug maker's plans to market a competing insulin injector pen in Australia.
The operator of a Vietnamese mine has filed a lawsuit seeking to enforce a $132 million arbitration judgment against engineering company Jacobs E&C, which was acquired by WorleyParsons in December.
Jones Day has bolstered its global disputes practice in Melbourne, bringing on experienced international dispute resolution lawyer Leah Ratcliff from BHP.
Otsuka Pharmaceuticals and Bristol Myers-Squibb can retain their defences in an ongoing patent dispute over antipsychotic drug Abilify, after the Federal Court dismissed a strike out bid by the Commonwealth of Australia over the allegedly "inconsistent" pleadings.